SOURCE: Cypress Bioscience, Inc.

Cypress Bioscience, Inc.

March 15, 2010 06:30 ET

Cypress Bioscience, Inc. to Present at Roth 22nd Annual OC Growth Stock Conference

SAN DIEGO, CA--(Marketwire - March 15, 2010) -  Cypress Bioscience, Inc. (NASDAQ: CYPB) today announced that Sabrina Martucci Johnson, its Chief Operating Officer and Chief Financial Officer, will present at the Roth 22nd Annual OC Growth Stock Conference on March 16, 2010.

The Roth conference is being held at the Ritz Carlton Laguna Niguel in Dana Point, CA. Ms. Johnson is scheduled to present on Tuesday, March 16th at 5:30pm Pacific Time. The audio broadcast of this presentation can be accessed at

A replay of the presentation will be available at the same web address as well as on Cypress' website,

About Cypress Bioscience
Cypress Bioscience, Inc. provides therapeutics and personalized medicine services, facilitating improved and individualized patient care. Cypress addresses the evolving needs of specialist physicians and their patients by identifying unmet medical needs in the areas of pain, rheumatology, and physical medicine and rehabilitation, including challenging disorders such as fibromyalgia and rheumatoid arthritis. This approach to improving patient care creates a unique partnership with physicians. Current products include Savella® (milnacipran HCI) and the Avise PG(SM) and Avise MCV(SM) therapeutic monitoring, diagnostic and prognostic tests for rheumatoid arthritis.

For more information about Cypress, please visit the Company's website at

Contact Information

  • For additional information please contact

    Mary Gieson, Investor Relations Manager
    (858) 452-2323
    Email Contact